Glimepiride, Alogliptin and Alogliptin+Pioglitazone Combination
Status:
Active, not recruiting
Trial end date:
2021-08-31
Target enrollment:
Participant gender:
Summary
- This trial is a three-armed, open label, random assignment trial.
- The research subjects are patients who are first starting their treatment or patients
who have failed with the metformin treatment and are changing their medication. They
will be assigned to one of the following treatment groups: the glimepiride monotherapy
treatment group, the alogliptin monotherapy treatment group, and the alogliptin -
pioglitazone combination therapy treatment group
- This trial is a prospective trial which will conduct surveys 6 times over the course of
the 6 months in which each treatment group is administered drugs (Week -2, Baseline,
Week 4, Week 12, Week 24, follow-up safety survey).
- This trial is a multicenter clinical trial which will be conducted at more than 5
general hospital medical institutions in the vicinity of the capital.